Biotransformation of Ginsenosides (Ginseng Saponins)

Fengxie Jin1 • Hongshan Yu1** • Yaoyao Fu1 • Dong Shan An1 • Wan-Tae Im2 • Sung-Taek Lee1 • Jaime A. Teixeira da Silva3

1 College of Biotechnology, Dalian Polytechnic University, Qinggong-yuan No 1, Ganjingzi-qu, Dalian 116034, People’s Republic of China
2 Environmental and Molecular Microbiology Laboratory, Department of Biological Sciences, Korea Advanced Institute of Science and Technology, 373-1 Guseong-dong, Yuseong-gu, Daejeon 305-701, South Korea
3 Faculty of Agriculture and Graduate School of Agriculture, Kagawa University, Miki cho, Kita gun, Ikenobe, 761-0795, Japan

Corresponding author: * fxjin@dlili.edu.cn; ** hongshan@dlili.edu.cn

Invited Review

Received: 24 November, 2009. Accepted: 26 July, 2011.

ABSTRACT

Ginseng is a famous herbal medicine. The major active ingredient of ginseng is ginsenoside, a ginseng saponin. After oral intake of ginseng, the major ginsenosides are hydrolyzed in the human intestinal tract into the more active minor ginsenosides, and the converted minor ginsenosides are absorbed. The minor ginsenosides such as ginsenoside C-K, Rh2, Rh1, Rg3, and Rg2 have special physiological and therapeutic activities that are readily used for ginseng medicines and health foods. This review introduces the biotransformation of ginsenosides into minor ginsenosides and introduces four newly developed types of ginsenosidases (ginseng saponin-glycosidases) i.e., ginsenosidase type I, which can hydrolyze multi-20-O-glycosides and 3-O-glycosides of the protopanaxadiol (PPD) type ginsenosides; ginsenosidase type II, which can hydrolyze multi-20-O-glycosides of the ginsenosides; ginsenosidase type III, which can hydrolyze 3-O-glucoside of the multi-PPD type ginsenosides; ginsenosidase type IV, which can hydrolyze multi-6-O-glycosides of the protopanaxatriol (PPT) type ginsenosides.

Keywords: ginseng, ginsenoside, ginsenoside biotransformation, ginsenosidase type I, II, III and IV, novel enzyme

CONTENTS

INTRODUCTION ........................................................................................................................................... 33
GINSENG AND GINSEenosides .................................................................................................................. 34
Ginsengs .................................................................................................................................................. 34
Ginsenosides .......................................................................................................................................... 34
Minor ginsenosides of red ginseng ........................................................................................................... 35
RHAEOMOCOLOGICAL ACTIVITIES OF MINOR GINSEenosides .............................................................. 36
Ginsenoside Rh2 and Rh3 .......................................................................................................................... 36
Ginsenoside C-K ...................................................................................................................................... 36
Ginsenoside Rh1 ...................................................................................................................................... 36
Ginsenoside Rg3 and Rg5 .......................................................................................................................... 37
Ginsenoside Rg2 ...................................................................................................................................... 37
GINSEenoside METABOLISM BY INTESTINAL FLORA .................................................................................. 37
GINSEenoside BIOTRANSFORMATION ...................................................................................................... 38
Ginsenoside enzymes in ginseng plants.................................................................................................. 38
Ginsenoside hydrolysis by culture broth of microorganisms ................................................................ 38
New special ginsenosides ....................................................................................................................... 39
CONCLUSION ........................................................................................................................................ 41
ACKNOWLEDGEMENTS .......................................................................................................................... 41
REFERENCES .......................................................................................................................................... 41

INTRODUCTION

Ginseng, the root of species of the Panax genus [including Panax ginseng C. A. Meyer, Panax quinquefolium L. (American ginseng), Panax notoginseng (Sanchi ginseng, or Tienchi ginseng), Panax japonicus], has been widely used as a “magic” herbal medicine for thousands of years.

The major active ingredients of ginseng are ginsenosides (ginseng saponins) of which over 50 components have been identified. Ginsenosides are categorized into three types: protopanaxadiol type ginsenosides (PPD), protopanaxatriol type ginsenosides (PPT), and oleanonic acid type ginsenoside.

Ginseng’s major ginsenosides, including ginsenoside Rh1, Rh2, Re, Rd, Re and Rg1, are found in ginseng, while minor ginsenosides such as 20(S) and 20(R)-Rg3, 20(S) and 20(R)-Rh2, 20(S) and 20(R)-Rh1, Rg2, Rk1, and Rg1 are found in red ginseng. Moreover, ginsenoside Rg5 and its derivatives such as Rh2, Rh3, Rg3, Rh1, Rg5 and Rh3 showing strong antitumor, antimetastatic, hepatoprotective, neuroprotective, immune-stimulating, anti-diabetes and vasodilating activities. It is generally agreed that the minor ginsenosides have high therapeutic and nutritional value (Jin 2009). Therefore, the minor ginsenosides are readily used for ginseng medicines and health foods.

However, it is very difficult to extract these minor ginsenosides from red and wild ginseng roots because the contents of rare ginsenosides in red and wild ginseng roots...
or Tienchi ginseng, mainly in Yunnan, Guizhou and Sichuan Provinces, American ginseng in China, America and Canada and notoginseng mainly planted in China, Korea, Russia and Japan, American ginseng and notoginseng are extremely low (Kitagawa et al. 1983). Moreover, after ginseng is taken orally, the ginseng saponins are hydrolyzed in the human intestinal tract by intestinal bacteria, where the major ginsenosides are converted into active forms of minor ginsenosides, which are subsequently absorbed. However, transformation of these minor ginsenosides in the human body is very low (Kanaoka et al. 1994).

Therefore, biotransformation of major ginsenosides such as Rb1, Rb2, Rc, Rd, Re and Rg1 to produce more active minor ginsenosides is a key factor for ginseng medicine and health foods.

To obtain more active minor ginsenosides, our lab developed new special ginsenosidases, which can be divided into four types: ginsenosidase type I, II, III and IV. These ginsenosidases are the focus of this review.

GINSENG AND GINSENOSIDES

Ginsengs

The main, widely used ginsengs include ginseng (Korea ginseng, *Panax ginseng* C. A. Meyer), American ginseng (*Panax quinquefolium* L.) and notoginseng (Sanchi ginseng, or Tienchi ginseng, *Panax notoginseng*). Korea ginseng is mainly planted in China, Korea, Russia and Japan, American ginseng in China, America and Canada and notoginseng mainly in Yunnan, Guizhou and Sichuan Provinces, China.

Other ginsengs such as *Panax japonicus* is rarely produced in Japan; wild *P. trifolius* L. is produced in Canada and America; *P. pseudoginseng* var. *angustifolius* Burk, *P. pseudoginseng* var. ‘Major Burk’, *P. pseudoginseng* var. *Zingibrtmis* C. Y. Wv. et. K. M. Feng, *P. pseudoginseng* var. *bip innatifidus* Seen and *P. stipulcanatus* Seem are produced to a small extent to the south of China, Vietnam and India (Wang 2001).

The planting of ginseng and main ginseng roots are shown in Figs. 1 and 2.

Ginsenosides

One of physiologically active materials of ginseng plants is a saponin, ginsenoside, 50 of which are known. Ginsenosides are divided into three types, namely protopanaxadiol (PPD) type and protopanaxatriol (PPT) type ginsenosides which are dammarane saponins, and oleanonic acid type saponins such as ginsenoside Ro. The ginsenosides Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Re, Rg1 are protopanaxadiol (PPD) type ginsenosides, while the oleanonic acid type ginsenoside Ro is shown in Figs. 3-5.

**Fig. 3** Protopanaxadiol (PPD) type ginsenosides. Modified from Jin (2009).

Ginsenosides are extremely low (Kitagawa et al. 1983). Moreover, after ginseng is taken orally, the ginseng saponins are hydrolyzed in the human intestinal tract by intestinal bacteria, where the major ginsenosides are converted into active forms of minor ginsenosides, which are subsequently absorbed. However, transformation of these minor ginsenosides in the human body is very low (Kanaoka et al. 1994).

Therefore, biotransformation of major ginsenosides such as Rb1, Rb2, Rc, Rd, Re and Rg1 to produce more active minor ginsenosides is a key factor for ginseng medicine and health foods.

To obtain more active minor ginsenosides, our lab developed new special ginsenosidases, which can be divided into four types: ginsenosidase type I, II, III and IV. These ginsenosidases are the focus of this review.

**GINSENG AND GINSENOSIDES**

**Ginsengs**

The main, widely used ginsengs include ginseng (Korea ginseng, *Panax ginseng* C. A. Meyer), American ginseng (*Panax quinquefolium* L.) and notoginseng (Sanchi ginseng, or Tienchi ginseng, *Panax notoginseng*). Korea ginseng is mainly planted in China, Korea, Russia and Japan, American ginseng in China, America and Canada and notoginseng mainly in Yunnan, Guizhou and Sichuan Provinces, China.

Other ginsengs such as *Panax japonicus* is rarely produced in Japan; wild *P. trifolius* L. is produced in Canada and America; *P. pseudoginseng* var. *angustifolius* Burk, *P. pseudoginseng* var. ‘Major Burk’, *P. pseudoginseng* var. *Zingibrtmis* C. Y. Wv. et. K. M. Feng, *P. pseudoginseng* var. *bipinnatifidus* Seen and *P. stipulcanatus* Seem are produced to a small extent to the south of China, Vietnam and India (Wang 2001).

The planting of ginseng and main ginseng roots are shown in Figs. 1 and 2.

**Ginsenosides**

One of physiologically active materials of ginseng plants is a saponin, ginsenoside, 50 of which are known. Ginsenosides are divided into three types, namely protopanaxadiol (PPD) type and protopanaxatriol (PPT) type ginsenosides which are dammarane saponins, and oleanonic acid type saponins such as ginsenoside Ro. The ginsenosides Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, Re, and Rg1 are PPT type ginsenosides; Re, Rg1, Rg2, Rg4, Rh1, Rh4 are PPT type ginsenosides. Ginsenosides Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, F2, Rg3, Rg5, Rh2, and Rh3 are PPD type ginsenosides; Re, Rg1, Rg2, Rg4, Rh1, Rh4 are PPT type ginsenosides. Ginsenosides Ra1, Ra2, Ra3, Rb1, Rb2, Rb3, Rc, Rd, F2, Re, Rg1 are dammarane 20(S)-saponins, but ginsenosides Rg3, Rh2, Rg2, Rh1 have 20(S) and 20(R)-forms (Wang 2001). The common structures of several compounds belonging to the ginsenosides are shown in Figs. 3–5.

Ginsenoside Rb1, Rb2, Rc, Rd, Re and Rg1 are dammarane 20(β)-forms (Wang 2001). The common structures of several compounds belonging to the ginsenosides are shown in Figs. 3–5.

Ginsenoside Ro is shown in Fig. 3 while the oleanonic acid type ginsenoside Ro is shown in Fig. 3. Protopanaxadiol (PPD) type ginsenosides. Modified from Jin (2009).
Fig. 5 Oleanonic acid type ginsenoside Ro. Modified from Jin (2009).

Although over 50 kinds of ginsenosides are known, only several contain the main, higher content ginsenosides in the drug ginseng. For example, over 90% of ginsenosides in Korea ginseng root consist of ginsenoside Rb1, Rb2, Rc, Rd, Re and Rg1, while the content of other ginsenosides is low; the main ginsenosides in American ginseng roots are ginsenoside Rb1, Re, Rc, Rd and Rg1; the ginsenosides in notoginseng roots are ginsenoside Rb1, Rg1, Rd and R1.

The content of ginsenosides differs depending on the breed, production area and planting year of ginseng. In our laboratory, ginsenoside content was examined using the roots of the marketable ginseng drug such as ginseng and American ginseng produced in Fusong, Jilin Province, China and notoginseng produced in Yunnan Province, China. The main ginsenosides content in ginseng drug is shown in Table 1.

There is a high content of ginsenoside Rb1, Rb2, Re, Rc, Rd, Re and Rg1 in ginseng, a high content of ginsenoside Rb1 and Re in American ginseng and a high content of ginsenoside Rb1 and R1 in notoginseng (Table 1).

The Pharmacopoeia of the People’s Republic of China (2005) prescribes the main ginsenosides contents of ginseng drug when analysed by HPLC: ginsenoside Rg1 and Re contents should not be < 0.3%, ginsenoside Rb1 should not be < 0.2%, the total content of ginsenoside Rg1, Re and Rb1 in American ginseng drug should not be < 2.0% and the total content of ginsenoside Rg1, Rb1 and R1 of notoginseng drug should not be < 2.0%.

Minor ginsenosides of red ginseng

Ginseng is generally used in the form of white ginseng which is prepared by drying fresh ginseng at room temperature, used in the form of red ginseng which is prepared by steaming fresh ginseng at 98-100°C for 1.5-2.5 h.

In red ginseng, when preparing fresh steamed ginseng, the 20(carbon)-O-glycoside of 20(S)-ginsenosides Rb1, Rb2, Rc, Rd, Re, Rg1, 6-Ac-Rb, 6-Ac-Rb2, 6-Ac-Re and 6-Ac-Rd of fresh ginseng are hydrolyzed to 20(S) and 20(R)-forms Rg3, Rh2, Rh1, Rs3; in addition, the 20(Carbon)-OH of minor ginsenoside 20(S) and 20(R)-forms Rg3, Rh2, Rh1 in red ginseng, Modified from Park et al. (1998).

The structure of minor ginsenosides is shown in Figs. 6.
However, after ginseng is consumed orally, ginseng saponins are hydrolyzed in human intestinal tract by intestinal bacteria, and the major ginsenosides are converted into the active forms of minor ginsenosides and are subsequently absorbed (Kanaoka et al. 1994; Bae et al. 2000). Therefore, the pharmaceutical activities of the minor ginsenosides such as ginsenoside C-K, Rh2, Rg1, Rg3, and Rg5 have received special attention recently, and are widely investigated as shown in the following sections.

**Ginsenoside Rh2 and Rh3**

Ginsenosides Rh2 and Rh3 have anti-cancer activity (Toda et al. 1993; Nakata et al. 1998). Ginsenosides Rh2 and Rh3 induced differentiation of HL-60 cells into morphological and functional granulocytes during leukaemia therapy (Kim et al. 1998). Ginsenosides Rh2 and Rh3 significantly inhibited the proliferation of human cervical adenocarcinoma HeLa cells (Fei et al. 2003; Yi et al. 2009), and prostate cancer LNCaP cells (Xie et al. 2006). Ginsenoside Rh2 induced a phenotypic reverse transformation in B16 melanoma cells (Fujikawa et al. 1987; Matsui et al. 1995) and arrested the activity of kinase 1 during apoptosis in human breast cancer cells, the MCF7 cells (Ham et al. 2006; Choi et al. 2009). Ginsenosides Rh2 and Rh3 had a differentiation-inducing capability on SK-HEP-1 human hepatoma cells in vitro and/or in vivo (Lee et al. 1996; Wu and Xie 2008). Ginsenoside 20(R)-Rh2 showed selective osteoclastogenesis inhibitory activity in RAW264 cells in vitro (Liu et al. 2009).

Ginsenosides Rh2 and Rh3 have an anti-inflammatory effect; they inhibited microglial cell activation in neurodegenerative diseases (Park et al. 2009). The anti-inflammatory activity of ginsenosides Rh3 and Rh2 was shown by the inhibited production of inflammatory mediators by suppressing the activation of tumor nuclear factor (TNF)-B and its upstream signaling cascade (Park and Cho 2009).

Furthermore, ginsenosides Rh2 and Rh3 also have other activities such as anti-obesity, anti-anaphylaxis, anxiety, anti-dementia and anti-CNS disease. Ginsenoside Rh2 is the most effective candidate for preventing metabolic disorders such as obesity and acts via the AMPK signaling pathway (Hwang et al. 2007). Ginsenoside Rh2 could promote the differentiation of preadipocytes by activating glucocorticoid receptor in 3T3-L1 cells (Niu et al. 2009). The anti-pruritic effects of Rh2 inhibit scratching behavior and vascular permeability in mice (Trinh et al. 2008). Ginsenosides Rh2 and Rh3 showed potent inhibition of mouse passive cutaneous anaphylaxis (Bae et al. 2006) and showed anti-hypertensive-like effects by antagonizing GABA/benzodiazepines in mice in the elevated plus-maze model (Kim et al. 2009).

**Ginsenoside C-K**

Compound K (C-K) enhances insulin secretion with beneficial metabolic effects in db/db mice (Shin and Kim 2005; Kang et al. 2007; Yoon et al. 2007). C-K offers protection from liver injury (Lee et al. 2005); ginsenoside Rh2 and C-K may improve ischemic brain injury (Baek et al. 2004); C-K has immunomodulatory effects (Yang et al. 2008).

Ginsenoside C-K has anti-cancer effects, specifically anti-tumor effects (Chai et al. 2007). C-K and Rh2 inhibit TNF and exert anti-inflammatory effects in human astroglial cells (Choi et al. 2007). Ginsenoside C-K is effective for the treatment of septicemia caused by Gram-negative bacteria, and can inhibit cell proliferation by inducing apoptosis and cell cycle arrest at the G1 phase in human monocyte leukemia cells (Kang et al. 2005, 2006).

C-K might prevent or improve deteriorations in health such as xerosis and wrinkles, partly ascribed to the age-dependent decrease of the hyaluronic (HA) content in human skin (Kim et al. 2004). C-K can improve scratching behaviors and chronic oxazolone-induced dermatitis or psoriasis.
rasis of mouse models (Shin et al. 2005; Yong et al. 2005). C-K suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair in human keratinocytes; C-K can also prevent skin aging and is superior in inhibiting the decomposition of the epidermal-dermal junction (Cai et al. 2008).

**Ginsenoside Rh1**

Ginsenoside Rh1 is an antioxidant inducing hemolysis (Sun et al. 2005, 2006). Ginsenoside Rh1 has anti-platelet aggregation activity in the treatment of cardio- and cerebro-vascular diseases (Wang et al. 2008).

Ginsenoside Rh1 activated the transcription of the estrogen-responsive luciferase reporter gene showing the greatest estrogenic effect in human breast carcinoma MCF-7 cells (Lee et al. 2003; Dong and Kiyama 2009). Ginsenoside Rh1 possesses characteristic effects on the proliferation of human leukemia cells (THP-1) (Popovich and Kitts 2002).

Ginsenoside Rh1 also showed anti-allergic, anti-inflammatory, immunomodulatory, and improving memory effects. The antiallergic action of ginsenoside Rh1 originated from its cell membrane-stabilizing and anti-inflammatory activities, which could improve the inflammation caused by allergens (Park et al. 2004; Kim et al. 2008). Ginsenoside Rh1 improved chronic dermatitis and psoriasis in mouse ear dermatitis models (Shin et al. 2006). Ginsenoside Rh1 significantly ameliorated memory-impaired models induced by scopolamine in mice and increased hippocampal excitability in the dentate gyrus of anesthetized rats, improving memory and hippocampal excitability (Lee et al. 2000; Wang et al. 2009).

**Ginsenoside Rg3 and Rg5**

Ginsenosides Rg3, Rg5 and Rk1 have various anti-cancer properties. Ginsenoside Rg3 inhibits angiogenesis and growth of lung cancer (Lu et al. 2008), TNF-β, and enhances the susceptibility of colon cancer cells to docetaxel and other chemotherapeutics (Kim et al. 2009; Lee et al. 2009; Xie et al. 2009). Ginsenosides Rg3, Rg5 and Rk1 arrest the cell cycle at the G1 phase in HeLa cells (Lee et al. 2009).

Ginsenosides Rg3, Rg5 and Rk1 distinctly inhibit lipid accumulation and are suitable for the therapy of hypercholesterolemia and triglyceridemia; Rg3 ginsenoside is the most effective at inhibiting lipid accumulation (Kim et al. 2009); ginsenoside Rg3 and C-K have distinct anti-ischemic effects (Kim et al. 2007); Rg3 inhibits platelet aggregation via the modulation of downstream signaling components such as cAMP and ERK2 (Lee et al. 2007), (20S)-ginsenoside Rg3, a neuroprotective agent, inhibits mitochondrial permeability transition pores in the rat brain (Tian et al. 2009), useful for treating patients suffering from Alzheimer’s disease (Yang et al. 2009). Ginsenoside Rk1 and Rg5 inhibited arachidonic acid (AA)-induced platelet aggregation in a dose-dependent manner, inhibited U46619 (thromboxane A2 mimetic agent)-induced platelet aggregation; and the ginsenoside 20(S)-Rg3 and 20(R)-Rg3 showed mild inhibitory activity against AA- and U46619-induced aggregation (Lee et al. 2009).

Ginsenoside Rg3 has an anti-diabetes effect by improving insulin signaling and glucose uptake primarily by stimulating the expression of IRS-1 and GLUT4 (Kim et al. 2009); Rg3 of red ginseng displays beneficial effects in the treatment of diabetes at least in part via the stimulation of insulin release in a glucose-independent manner (Kim and Kiyama 2008); 20(S)-Rg3 has beneficial effects on diabetic renal damage with an inhibitory effect against NMDA receptor-mediated nitrosative stress (Kang et al. 2008).

**Ginsenoside Rg2**

Ginsenoside Rg2 can protect human erythrocytes against hemin-induced hemolysis (Li et al. 2008) and as an antioxidant, it can also prolong the lag time of hemolysis (Liu et al. 2002).

Rg2 induces gap junction-mediated intercellular communication (Zhang et al. 2001), exerts effects on the immune responses to ovalbumin (OVA) in mice (Sun et al. 2007) and can act as a prooxidant (Liu et al. 2003). Ginsenoside-Rg2 protects against memory impairment (Zhang et al. 2008), and protects cells against UVB-induced genotoxicity by increasing DNA repair and decreasing apoptosis (Jeong et al. 2007) and hydrogen peroxide-induced cytotoxicity of human umbilical cord vein endothelial cells in vitro (Xin et al. 2005).

Rg2 might regulate the 5-HT3A receptors that are expressed in Xenopus oocytes and its regulation might be one of the pharmacological actions of P. ginseng (Lee et al. 2004). Rg2 also regulates glycine receptor which is expressed in Xenopus oocytes (Noh et al. 2003).

These studies indicate that the minor ginsenosides from red ginseng have pharmacological and physiological activities which can be readily used for ginseng medicine and health foods.

**GINSENSOSIDE METABOLISM BY INTESTINAL FLORA**

After ginseng is consumed orally, the ginsenosides are hydrolyzed in the human intestinal tract by intestinal bacteria, and the major ginsenosides such as Rb1, Rb2, Rc, Rd, Re and Rg1 are converted into active forms of minor ginsenosides and are subsequently absorbed (Kanaoka et al. 1994; Bea et al. 2000, 2005; Chi et al. 2005).

The PPD type ginsenosides Rb1, Rb2, Rc and Rd are gradually hydrolyzed by intestinal bacteria (Kanaoka et al. 1994; Bea et al. 2000, 2005; Fig. 9). Ginsenosides Rb1, Rb2, Rc and Rd are gradually hydrolyzed: i.e., the 20-O-β-D-glucoside of ginsenoside Rb1, 20-O-α-L-arabinopyranoside of ginsenoside Rb2, and the 20-O-α-L-arabinofuranoside of ginsenoside Rc are hydrolyzed to ginsenoside Rd; then, the 3-O-β-D-glucoside of ginsenoside Rd is further hydro-

![Fig. 9 Metabolism of ginsenoside Rb1, Rb2, Re and Rd in intestinal tract by intestinal bacteria. Based on Kanaoka et al. (1994) and Bea et al. (2000, 2005).](image1)

![Fig. 10 Metabolism of ginsenoside Re and Rg1 in intestinal tract by intestinal bacteria. Based on Kanaoka et al. (1994) and Chi et al. (2005).](image2)
lyzed to ginsenoside F2; the 3-O-β-D-gluco-side of F2 is further hydrolyzed to C-K; and C-K is hydrolyzed to aglycone.

The PPT type ginsenosides Re and Rg1 are also gradually hydrolyzed by intestinal bacteria (Kanaoka et al. 1994; Chi et al. 2005; Fig. 10). The 6-O-α-L-rhamnose of ginsenoside Re is hydrolyzed to Rg1; the 6-O-β-D-glucoside of Rg1 is hydrolyzed to F1, or the 20-0-β-D-glucoside of Rg1 is hydrolyzed to Rh1; ginsenosides Rh1 and F1 are hydrolyzed to aglycone.

Therefore, after orally intake of ginseng, human bodies do not at first absorb the major ginsenosides such as Rb1, Rb2, Rc, Rd, Re and Rg1, but only absorb the converted minor ginsenosides. This proves that the pharmacological effects of ginseng on human bodies are the action of the converted ginsenosides, i.e., the action of the minor ginsenosides.

**GINSENOSIDE BIOTRANFORMATION**

From the above it is clear that the minor ginsenosides have special physiological and therapeutic activities. Thus, the conversion of the major ginsenosides in ginseng into more active minor ginsenosides is very important for the production of ginseng medicines and health foods. To obtain highly active minor ginsenosides, the biotransformation of ginsenosides is explained in detail next.

**Ginsenoside enzymes in ginseng plants**

The ginsenoside enzymes of ginseng plants can be divided into two types: one type of enzymes is related to ginseno-side biosynthesis during ginseng growth; the other type of enzymes is related to the hydrolysis of the ginsenoside-sugar moiety.

Zhang and Yue (2005) reported the enzymes related to ginsenoside biosynthesis in ginseng cells, specifically a new enzyme UDP-glucose ginsenoside Rd glucosyltransferase from notoginseng (Yue and Zhang 2005) and protopanaxadiol 6-hydroxylase (Yue et al. 2008). These enzymes related to ginsenoside biosynthesis are very usable for ginseng cell growth since they allow ginseng cells with a high content of ginsenosides to be obtained.

Our laboratory previously purified and characterized new ginsenosidases hydrolyzing ginsenoside sugar-moieties from the fresh roots of ginseng (Zhang et al. 2001, 2002). A new ginsenosidase hydrolyzing the 3-0-β-D-(1→2)-glucoside of the ginsenoside Rg3 sugar moiety to ginsenoside Rh2 had a molecular weight of about 59 kDa. Another ginsenosidase hydrolyzing the 20-0-β-D-(1→6)-arabinofuranoside of ginsenoside Rc to ginsenoside Rd was isolated from ginseng roots, purified and characterized. The enzyme molecular weight was about 86 kDa; the enzyme also hydrolyzed the 20-0-glycoside of ginsenosides Rb1 and Rb2.

The possibility of utilizing the ginsenosidases of ginseng itself in ginseng product preparation is very valuable for increasing the content of the more active minor ginsenosides in ginseng products. In order to make the most of ginseng itself, the use of ginsenosidases in the red ginseng process and in the new red ginseng process have been patented (Jin et al. China Patent No. ZL200510136799.8; title, Preparation of new active red-ginseng). The new red ginseng and its products contained a higher content of more active and easy-to-absorb minor ginsenosides although the external appearance and color were the same as traditional red ginseng.

**Ginsenoside hydrolysis by culture broth of microorganisms**

Studies on the hydrolysis of ginsenoside-sugar moieties using concentrated cultures fermented by microorganisms (crude enzyme), mainly fungus and bacteria, were carried out 30 years ago: crude hesperidinase, naringinase, pectinase, amylace and cellulase, and a concentrated culture broth of the microorganisms from soil could hydrolyzed ginsenosides Rb1, Rb2, Rc to give C-K or its aglycone; hydrolysis of Rg1 gave its aglycone (Kohda and Tanaka 1975). The concentrated culture broth (or crude enzyme) of Aspergillus oryzae and Penicillium sp. strain also hydrolyzed ginsenoside Re into ginsenoside Rg1, Rh1 and F1, respectively (Ko et al. 2003). The culture broth of the Mucilaginibacete composti sp. nov. could convert ginsenoside Re to gypenoside XVII (Cheng et al. 2007). The biotransformation of ginsenosides by microorganisms was reviewed by Park et al. (2010).

Our laboratory and the laboratory of Professor Sung-Taik Lee, KAIST (Korea Advanced Institute of Science and Technology), carried out a cooperation study on the hydrolysis of ginsenosides using 20 kinds of strains isolated from soil as explained in some detail next (Shao et al. 2008; Yu et al. 2008; Wang et al. 2009; Wu et al. 2009).

The 16S rRNA gene sequence of 20 kind new strains showed different levels of similarity to the same sequence in other microorganisms. Specifically, sp. No. 1, GS3020: 98.4% similarity with Arthrobacter chlorophenolicus A-6; sp. No. 2, GS3047: 96.9% similarity with Arthrobacter chlorophenolicus A-6; sp. No. 3, GS2020: 98.4% similarity with Arthrobacter chlorophenolicus A-6; sp. No. 4, GS3031: 99.8% similarity with Arthrobacter oxydans DSM20119T; sp. No. 5, GS2020: 99.8% similarity with Arthrobacter oxydans DSM20119T; sp. No. 6, GS0586: 95.7% similarity with Arthrobacter sacebranti CCM 2783T; sp. No. 7, GS0501: 96.9% similarity with Arthrobacter sacebranti CCM 2783T; sp. No. 8, GS0257: 96.1% similarity with Arthrobacter sacebranti CCM 2783T; sp. No. 9, GS0251: 99.8% similarity with Streptomyces exfoliantis NRRL B-1237T; sp. No. 10, GS0213: 99.8% similarity with Streptomyces polychromogenes NRRL B-3032T; sp. No. 11, GS0090 W1-04: 99.0% similarity with Mycobacterium mucogenicum ATCC49650 T; sp. No. 12, GS0121 W3-12: 99.1% similarity with Mycobacterium mucogenicum ATCC49650 T; sp. No. 13, GS0053 M1-23: 98.7% similarity with Rhodanobacter fulvis Jip2 T; sp. No. 14, GS3054: 98.5% similarity with Rhodanobacter fulvis Jip2 T; sp. No. 15, GS0053 M2-06: 97.0% similarity with Pedobacter himalayensis HHS 22T; sp. No. 16, GS3078: 98.6% similarity with Burkholderia caribienensis MWA64 T; sp. No. 17, GS0262: 97.9% similarity with Lentzea waywayandensis NRRL B-16159 T; sp. No. 18, Terrabacter ginsenosidimutans GS020 (An et al. 2010); sp. No. 19, GS1547: 100% similarity with Variovorax paradoxus W-50 T; sp. No. 20, GSB71: 98.71% similarity with Enterobacter asbriae ICM6051T.

To select good strains which produce the enzyme hydrolyzing sugar-moiety of ginsenosides, a culture broth of the 20 kinds of strains were cultured in the medium (tryptone, 10 g, yeast extract 5 g, NaCl 10 g, water 1000 ml) at 25°C for 2 days then reacted with 0.5% of ginsenoside Rb1, as shown in Fig. 11 (Yu et al. 2008). Also shown in Fig. 11 is that the culture broth of sp. No. 3, 14 and 18 strains obviously hydrolyzed ginsenoside Rb1; therefore, sp. No. 3, 14 and 18 strains were used in further studies. The culture broth of sp. No. 3, 14 and 18 strains in R2A medium cultured at 25°C for 6 days were also reacted with 0.5% of ginsenoside Rb1, as shown in Fig. 12. The culture broth of sp. No. 3 and 18 strains converted ginsenoside Rb1 into Rf, the culture broth of sp. No. 14 converted ginsenoside Rb1 into Rd. These facts prove that sp. No. 3 and 18 strains produce an enzyme capable of hydrolyzing two 20-O-gluco-sides of ginsenosides Rb1 into ginsenoside Rg3 while sp. No. 14 strain produces an enzyme hydrolyzing one 20-O-gluco-side of Rb1 into ginsenoside Rd.

To assess the effects of fermentation conditions such as medium and fermentation temperature on enzyme production and to analyze the hydrolysis of culture broth on different ginsenosides, enzyme fermentation conditions and
The culture broth also capable of hydrolyzing ginsenoside Rg1 into F1. Therefore, the culture broth was also capable of hydrolyzing ginsenoside Rh2 and gypenoside XVII production was confirmed at 35°C, the culture broths hydrolyzed ginsenosides mainly into ginsenoside Rg3; when these strains were fermented at 25°C, the culture broths hydrolyzed ginsenosides Rb1, Rb2, Rc and Rd. No. 3 and 18 strains were fermented at 25°C, the culture broth not only hydrolyzed ginsenoside Rb1, but also hydrolyzed other PPD type ginsenosides such as Rb2, Rc and Rd.

To obtain active minor ginsenosides from a high content of major ginsenosides in ginseng, it is necessary to recognize ginsenosidases from the culture broth of microorganisms or crude enzymes from animals and plants. Since the crude enzyme or culture broth of microorganisms have a large number of enzymes, it is not possible to produce the desired minor ginsenoside from a major ginsenoside.

Our laboratory has been studying the special ginsenosidases hydrolyzing ginsenoside sugar moieties, their fermentation, isolation, purification and characterization (Yu et al. 1999, 2002; Zhang et al. 2001, 2002; Jin et al. 2003; Yu et al. 2004; Yang et al. 2007; Yu et al. 2007; Wang et al. 2009; Yu et al. 2009; Wang et al. 2011).

Others (Hu et al. 2007) reported a new special ginsenosidase from the China white jade snail (Achatina fulica) hydrolyzing ginsenoside Rb1 into Rd, F2 and C-K; Cheng et al. (2008) reported an enzyme converting major ginsenoside Rb1 to 20(S)-ginsenoside Rg3 from Microbacterium sp. GS514.

The new ginsenosidases can be divided into four types:

**Ginsenosidase type I**, **II**, **III** and **IV** based on the hydrolyzing glycoside position of ginsenoside molecule as detailed next.

**Ginsenosidase type I** can hydrolyze multi-20-O-glycosides and 3-O-glycosides of PPD type ginsenosides such as Rb1, Rb2, Rb3, Rc, Rd, F2 and Rg3; i.e., ginsenosidase type I can hydrolyze the 20(carbon)-O-β-(1→6)-d-glucoside of Rb1, the 20-O-α-(1→6)-l-arabinoside(p) of Rb2, the 20-O-α-(1→6)-l-arabinoside(f) of Rc and the 20-O-β-(1→6)-D-xylloside of Rd to ginsenoside Rd; further, it can hydrolyze the 3-O-β-(1→2)-D-glucosides of Rd to F2 and the 3-O-D-glucosides of F2 mainly to C-K. The enzyme molecular weight from Aspergillus strain was about 80 kDa (Yu et al. 2007). The Ginsenosidase type I reaction is shown in Fig. 13. It is shown in Fig. 13 that ginsenosidase type I hydrolyzed multi-20-O-glycosides and 3-O-glycosides of the PPD type ginsenoside Rb1, Rb2, Rb3, Rc, Rd to mainly produce ginsenoside F2 and C-K; despite the enzyme faintly hydrolyzing ginsenoside F2 to Rh2, and faintly hydrolyzing C-K to its aglycone. Ginsenosidase type I also hydrolyzed the 3-O-β-(1→2)-D-glucosides of ginsenoside Rg3 to mainly produce ginsenoside Rh2, as shown in Fig. 14.

**Ginsenosidase type II** can hydrolyze multi-20-O-glycosides of ginsenosides.

The special ginsenosidase whose molecular weight is about 60 kDa, was purified and characterized from an Aspergillus strain (Yu et al. 2009) and specifically hydrolyzes multi-20-O-glycosides of PPD type ginsenosides such as ginsenoside Rb1, Rb2, Rb3 and Rc; i.e., ginsenosidase type...
II can hydrolyze the 20(carbon)-O-β-(1→6)-D-glucoside of Rb1, the 20-O-α-(1→6)-L-arabinoside(p) of Rb2, the 20-O-α-(1→6)-L-arabinoside(f) of Rc and the 20-O-β-(1→6)-d-xyloside of Rb3 to ginsenoside Rd; the enzyme further faintly hydrolyzes the 20-O-β-d-glucoses of Rd to produce a small quantity of ginsenoside Rg3; however, the enzyme could not hydrolyze the 20-O-glycosides of Rb3, as shown in Fig. 15. Fig. 15 also shows that ginsenosidase type II from the Aspergillus strain hydrolyzed multi 20-O-glycosides of PPD ginsenosides such as Rb1, Rb2, Rc and Rb3 mainly to produce ginsenoside Rd; the enzyme further faintly hydrolyzed the 20-O-β-d-glucoses of Rd to produce a small quantity of ginsenoside Rg3; however, the enzyme could not hydrolyze the 20-O-glycoside of the PPT type ginsenosides Rf and Rg1 (Yu et al. 2009).

However, the enzyme from bacteria such as Microbacterium sp. GS514 strain (Cheng et al. 2008), sp. No. 3, GS0202 (98.4% similarity of the 16S rRNA gene sequence with Arthrobacter chlorophenolicus A-6) and sp. No. 18, Terrabacter ginsenosidimutans sp. nov GS3082 (Shao et al. 2008; Yu et al. 2008; An et al. 2010) strains hydrolyzed multi 20-O-glycosides of PPT ginsenosides such as Rb1, Rb2, Rc and Rb3 mainly to produce ginsenoside Rg3 which could be used for Rg3 production.

Although ginsenosidase type II from the Aspergillus strain only hydrolyzed 20-O-glycoside of the PPD type ginsenoside, it did not hydrolyze the 20-O-glycoside of the PPT type ginsenosides Re and Rg1; however, our laboratory recognized that the special enzyme from bacteria such as Microbacterium sp. GS514 strain, sp. No. 3, GS0202 and sp. No. 18, T. ginsenosidimutans sp. nov GS3082 strains could hydrolyze the 20-O-glycoside of the PPT ginsenosides Re and Rg1 to respectively produce ginsenoside Rg2 and Rh1, as shown in Fig. 16.

Ginsenosidase type II might have two sub-enzymes: one that can only hydrolyze multi 20-O-glycosides of PPD type ginsenosides; the other that can hydrolyze 20-O-glucoside of PPT type ginsenosides Re and Rg1, but these needing further characterization.

**Ginsenosidase type III** can hydrolyze 3-O-glucosides of PPD type ginsenosides.

Our laboratory and the laboratory of Professor Sung-Taik Lee of KAIST (Korea Advanced Institute of Science and Technology) carried out a cooperation study on the special enzyme hydrolyzing 3-O-glucosides of PPD type ginsenosides. The enzyme gene (bgl-gyp17) comprising 1770 bp from Terrabacter ginsenosidimutans sp. nov GS3082 strain was cloned and overexpressed in Escherichia coli cells. The recombinant enzyme of a polypeptide consisted of 589 amino acids (An et al. 2010).

The recombinant enzyme examined in our laboratory could selectively hydrolyze 3-O-sugar-moiety of protopanaxadiol (PPD) type ginsenosides such as Rb1, Rb2, Rc, Rd, F2, Rg3, and Rh2 but it could hardly hydrolyze the 20-O-sugar-moiety of PPT type ginsenosides. The enzyme hydrolysis of ginsenoside Rb1, Rb2, Rc and Rd is shown in Fig. 17, which indicates that recombinant ginsenosidase selectively hydrolyzed 3-O-glucosides of ginsenosides Rb1, Rb2, Rc and Rd; i.e., the new enzyme hydrolyzed the 3-O-β-(1→2)-D-glucoside of ginsenoside Rb1 to gypenoside XVII and further hydrolyzed 3-O-β-D-glucoside of gyp XVII to gyp LXXV; it hydrolyzed the 3-O-β-(1→2)-D-glucoside of ginsenoside Rb2 to Compound-O (C-O) and further hydrolyzed the 3-O-β-D-glucoside of C-O to Compound-Y (C-Y); it hydrolyzed the 3-O-β-(1→2)-D-glucoside of ginsenoside Rc to Compound-Mc1 (C-Mc1) and further hydrolyzed the 3-O-β-D-glucoside of C-Mc1 to Compound-Mc (C-Mc); the enzyme also hydrolyzed the 3-O-β-(1→2)-D-glucoside of ginsenoside Rd to F2 and further hydrolyzed the 3-O-β-D-glucoside of Rd to C-K. The enzyme reaction is shown in Fig. 18. Ginsenosidase type III also hydrolyzed the 3-O-β-D-glucoside of ginsenoside Rg3 to Rh2 and further hydrolyzed it to its aglycone.

In summary, the ginsenosidase type III enzyme could selectively hydrolyze 3-O-β-D-glucoside of PPD type ginsenosides such as Rb1, Rb2, Rc, Rd, F2 and Rg3, but could not hydrolyze the sugar-moiety of PPT type ginsenosides.

**Ginsenosidase type IV** can hydrolyze the multi-6-O-glycosides of PPT type ginsenosides.

Our laboratory previously purified and characterized ginsenoside-α-rhamniosidase from a fungal strain (Yu et al. 2008; An et al. 2010).
**Table 2 Major ginsenosidases.**

<table>
<thead>
<tr>
<th>Enzyme type</th>
<th>Enzyme source</th>
<th>Hydrolyzing main glycoside position in ginsenoside</th>
<th>Hydrolyzing main glycoside</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ginsenosidase type I</td>
<td>Microorganism</td>
<td>3-O-(Carbon)-glycoside</td>
<td>Glc, Ara, Xyl</td>
</tr>
<tr>
<td>Ginsenosidase type II</td>
<td>Microorganism</td>
<td>20-O-(Carbon)-glycoside</td>
<td>Glc, Ara, Xyl</td>
</tr>
<tr>
<td>Ginsenosidase type III</td>
<td>Microorganism</td>
<td>3-O-(Carbon)-glycoside</td>
<td>Glc</td>
</tr>
<tr>
<td>Ginsenosidase type IV</td>
<td>Microorganism</td>
<td>6-O-(Carbon)-glycoside</td>
<td>Rha, Glc, Xyl</td>
</tr>
</tbody>
</table>

Fig. 19 Ginsenosidase type IV hydrolysis of ginsenoside Re, Rf, notoginsenoside R1 and Rg2. Based on Yu et al. (2002), Jin et al. (2003), and Wang et al. (2009, 2011).

2002). The enzyme not only hydrolyzed the 6-O-(1→2)-α-L-rhamnoid of ginsenoside Re to Rg1, but also hydrolyzed the 6-O-(1→2)-β-D-glucoside of ginsenoside Rf, and hydrolyzed the 6-O-(1→2)-β-D-xylodose of the noto-ginsenoside R1 to Rg1 (Jin et al. 2003; Wang et al. 2009, 2011); thus, the enzyme was a true ginsenosidase type IV hydrolyzing multi-6-O-glycosides of PPT type ginsenosides, as shown in Fig. 19.

Ginsenosidase type IV also hydrolyzed the 6-O-(1→2)-α-L-rhamnoid of ginsenoside Rg2 to Rh1; it also slightly hydrolyzed the 6-O-glucoside of ginsenoside Rg1 and Rh1 to respectively produce F4 and PPT aglycone. However, the enzyme from bacteria highly hydrolyzing Rg1 to F4 needs further studies.

In summarizing, new novel ginsenosidases hydrolyzing the sugar-moieties of ginsenosides selected the glycoside-position in the ginsenoside molecule but did not select glycosidic bonds; the ginsenosidases that hydrolyzed multi-glycosides of ginsenosides are shown in Table 2.

Ginsenosidase type I can hydrolyze multi-20-O and 3-O-glycosides of PPD type ginsenosides; Ginsenosidase type II can hydrolyze multi-20-O-glycosides of the ginsenosides; Ginsenosidase type III can hydrolyze 3-O-glycosides of PPD type multi-ginsenosides; Ginsenosidase type IV can hydrolyze multi-6-O-glycosides of PPT type ginsenosides.

These properties of ginsenosidases differentiate them from those of glycosidases: one type of enzyme hydrolyzes one type of glycoside, as described in the Enzyme Nomenclature by NCIUBMB (Nomenclature Committee of the International Union Biochemistry and Molecular Biology described in http://www.qmul.ac.uk/ubmb/enzyme); therefore, ginsenosidases are a new novel class of glycosidases which can be used for the production of minor ginsenosides.

It is possible to produce active minor ginsenosides using the new special ginsenosidases by controlling the enzyme reaction time, temperature and substrate concentration.

**CONCLUSION**

This review shows that the major ginsenosides that exist in high concentrations in ginseng are ginsenosides Rb1, Rb2, Rc, Rd, Re and Rg1; the major minor-ginsenosides in red ginseng are Rg3, Rg5 and Rk1, Rh2, Rh3 and Rk2, Rg2, Rg4(F4) and Rg6, Rh1, Rh4 and Rk3; after ginseng is consumed orally, the human body does not first absorb the major ginsenosides such as Rb1, Rb2, Rc, Rd, Re and Rg1; rather, it only absorbs the converted minor ginsenosides. This proves that the pharmacological effects of ginseng on the human body are in fact the action of the converted ginsenosides, i.e., the action of the minor ginsenosides.

The minor ginsenosides from red ginseng have very good pharmacological and physiological activities. Therefore, biotransformation of the major ginsenosides into more active minor ginsenosides is very important for ginseng medicine and health food.

It is possible that the available active minor ginsenosides can be produced using new special ginsenosidases (Types I-IV) under controlled conditions.

The biotransformation of ginsenosides and new ginsenosidases indicate that it is potentially possible to bio-transform thousands of other saponins or glycosides in herbs (Kanpo) into more active converted products.

**ACKNOWLEDGEMENTS**

This work was financially supported by projects of the National Natural Science Foundation of China (NSFC) No. 38970010, No. 39370010, No. 2977010, No. 2007600, No. 30371744, and No. 30470055 and also supported by the Program for Liaoning Innovative Research Team in University (LNIRT): No. 2007T1006, No. 2008T008, No. 2009T007, No. LT2010009.

**REFERENCES**


Chai RH, Jiang BH, Zhao YP (2007) Anti-tumor effects of ginsenoside compound K and the enzymatic transformed products from the total saponins in leaves of Panax notoginseng by glucanase. Zhongguo Xian dai Zhong Yao, 14-16


brial conversion of ginsenoside Rb1 to minor Ginsenoside F2 and Gypenoside XVII by Intraperospongium sp. GS603 isolated from soil. Journal of Biological and Biotechnology 17, 1937-1943


Cui CH, Choi TE, Yu HS, Jin FX, Kim SC, Im WT (2011) Mucl


Gao QG, Chen WF, Xie JX, Wong MS (2009) Ginsenoside Rg1 protects against 6-OHDA-induced neurotoxicity in neuroblastoma SK-N-SH cells via IGF-1 receptor and estrogen receptor pathways. Journal of Neurochemistry 103, 327-335


Kim MA, Byung YJ, Yi J, S, CS, Lim S, Park SG, Jung HS, Lee HK, Park KB (2009) The ginsenoside Rh3 has a stimulatory effect on insulin signaling in L6 myotubes. Biochemical and Biophysical Research Communications 389, 70-73

Kim MS, Kwon B, Park MS, Ji GE (2008) Isolation of ginsenoside Rh1 and compound K from fermented ginseng and efficacy assessment on systemic antiphlogistic effect. Biochemical and Biophysical Research Communications 364, 348-355

Kim SM, Lee SY, Yoon D, Moon DC, Choi SS, Kim Y, Han SB, Oh KW, Hong JT (2009) Inhibition of NF-κB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel. Archives of Pharmacal Research 32, 755-766


Kohda H, Tanaka O (1975) Enzymatic hydrolysis of ginsenosides and their related glycosides. Yakkazhi Zashhi 95, 246-249


Matsui T, Kohno H, Ota T (1995) Reduced sialylation of peanut agglutinin-binding sugar chains on CD44 associated with enhanced adhesiveness to endothelial cells and experimental metastatic ability in B16B6 melanoma cells. Kkanwana Ik Daigaku Zasshi 20, 194-204
Park YK, Cho EA, Han MJ, Kim DH (2004) Ginsenoside Rb1 possesses antiallergic and anti-inflammatory activities. International Archives of Allergy and Immunology 133, 113-120

